Endocrine Abstracts

One in eight hundred young adults is now a survivor of childhood cancer as a result of tremendous advances in cancer therapy. However, this success now brings with it the challenge that both the cancer and its therapy may have late effects. In a recent review of 10 397 young adult survivors, 62.3% had at least one chronic condition; 27.5% had a severe or life-threatening condition (grade 3 or 4). The adjusted relative risk of a chronic condition in a survivor, as compared with siblings, was 3.3 (95% CI, 3.0 to 3.5); for a severe or life-threatening condition, the risk was 8.2 (95% CI, 6.9 to 9.7). Among survivors, the cumulative incidence of a chronic health condition reached 73.4% (95% CI, 69.0 to 77.9) 30 years after the cancer diagnosis, with a cumulative incidence of 42.4% (95% CI, 33.7 to 51.2) for severe, disabling, or life-threatening conditions or death. Owing to a chronic condition. Thus, late effects are common and many of these late effects are endocrine in nature including; hypogonadism, infertility and hypopituitarism. This expert session will address the management of endocrine late effects following cancer therapy.